The main objective of this trial is to investigate: * the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs. Avenciguat (BI 685509) iCF (Test 1, T1) tablets under fasted conditions * the relative bioavailability of Avenciguat (BI 685509) iCF tablets under fasted (T1) and fed (Test 2, T2) conditions * the relative bioavailability of Avenciguat (BI 685509) iCF tablets given alone (T1) and together with esomeprazole (Test 3, T3) under fasted conditions
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Avenciguat (BI 685509) (intended commercial formulation (iCF))
Avenciguat (BI 685509) (trial formulation 2 (TF2))
esomeprazole (Nexium mups)
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: Up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to 4 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.